Replies to post #176527 on Biotech Values

[oc631]

IF NVS really thought IDIX were worthless, it presumably could've worked out a partial or full sale of its stake to Baupost or another institutional holder. Maybe NVS is holding for the possibility of an IP royalty on Sovaldi.

So you think the Baupost group isn't having second thoughts or regrets? The days of averaging down on bad investments and pumping up the stock price (along with the the momo crowd) are nearing an end. I suspect if either party (including Baupost) could get out cleanly at the current market price they would be gone. GILD will challenge IDIX's IP in Europe and the U.S. (if the company ever gets off the FDA's blacklist). If the IDX-437/Sovaprevir combo proves safe how will it fair against Sovaldi/Ledipasvir in non-inferiority studies? How much money will IDIX need to raise to run these studies? What will their legal costs be defending their IP position?